Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Dr. Peter Dicpinigaitis Appointed to the Advisory Board

<< Previous

Bullboard Posts

Next >>

Comment by waves1on Jan 11, 2023 3:09pm

64 Views

Post# 35216601

RE:Dr. Peter Dicpinigaitis Appointed to the Advisory Board

Definitely. It's notable that while he has extensive experience in all aspects of clinical medicine, a major focus of his clinical research for over 25 years has been in the area of cough, aligning directly with his work on AGN's Phase 2b chronic cough study.

<< Previous

Bullboard Posts

Next >>

Gold, growth and sustainability in focus for Mandalay Resources